bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.120
+1.050 (98.13%)
At close: Mar 13, 2026, 4:00 PM EDT
1.951
-0.169 (-7.96%)
After-hours: Mar 13, 2026, 7:59 PM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$108,105
Profits / Employee
-$261,575
Market Cap
9.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| FONAR | 535 |
| XWELL | 312 |
| MDxHealth | 312 |
| Exagen | 215 |
| Precipio | 60 |
| Insight Molecular Diagnostics | 49 |
| Advanced Biomed | 31 |
BIAF News
- 22 hours ago - bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
- 1 day ago - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Business Wire
- 4 days ago - bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - Business Wire
- 10 days ago - bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - Business Wire
- 16 days ago - bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - Business Wire
- 22 days ago - New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer - Business Wire
- 25 days ago - Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study - Business Wire
- 4 weeks ago - bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Business Wire